November 2015 Newsletter
Boehringer Ingelheim IASLC Chinese Fellowship Award
Applications are now welcome for the Boehringer Ingelheim IASLC Chinese Research Fellowship Award. It is one award for one year for a Chinese applicant to be funded with $40,000 by Boehringer Ingelheim to work in a U.S./EU major center in order to obtain laboratory skill and collaboration. The goal is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer.
IASLC Fellowship/Young Investigator Awards
Applications are now welcome for the 2016-2017 Fellowship and Young Investigator Awards. There will be a minimum of three one-year awards of $40,000, with at least one recipient from each region (North America, Europe and the rest of the world). The funding period will be July 1, 2016–June 30, 2017. The goal is to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine. Applications will be evaluated by a Scientific Review Panel for their merit, innovation and potential impact on the management of lung cancer.
The deadline to submit is now extended to Jan. 15, 2016. Click here for more information.
IASLC-ALCF Joint Fellowship: $150,000 Per Year for 2 Years
As we first announced at the WCLC, the IASLC is partnering with the Bonnie J. Addario Lung Cancer Foundation (ALCF) to announce a new $300,000, two-year fellowship to support an early-career scientists to conduct research on early detection modalities for lung cancer.
The deadline to submit is Nov. 30, 2015. Click here for more information.
Best of WCLC 2015
European Lung Cancer Conference 2016
Asia Pacific Lung Cancer Conference 2016
The IASLC APLCC Research Fellowship Award is a one-year $40,000 award for an applicant from Southeast Asia. The APLCC grant allows an applicant to work in in the U.S. or EU to obtain laboratory skills and develop collaborations. The deadline to submit is Dec. 15, 2015. Announcement | Details
Latin American Lung Cancer Conference 2016
In the past four months, 11 different locations around the world have hosted Best of WCLC sessions. These highlight the presentations given at the 16th World Conference on Lung Cancer in Denver in September. Five more events are planned for 2016.
The picture on the right is from the Best of WCLC in Shenzhen, China on Oct. 25.
For more information about our Best of WCLC programs, please click here.
SWOG Lung Committee Change
Dr. Karen Kelly is the new chair of the Lung Committee of SWOG. She takes over the role from Dr. David Gandara. Both are with the UC Davis Comprehensive Cancer.
Dr. Gandara is the longest running leader at SWOG, having chaired the SWOG Lung Committee for 17 years before announcing in September that he is stepping down. Dr. Gandara is also a former IASLC President and current IASLC Treasurer.
Dr. Kelly's new SWOG position takes effect Jan. 1, 2016. She has been a SWOG member since 1992 and is currently the committee’s medical oncology lead.
SWOG, which originated in the Southwest and was previously known as the Southwest Oncology Group, is a National Cancer Institute-supported clinical research cooperative group. It has roughly 5,000 affiliated physician researchers, as well as thousands of oncology research professionals from more than 650 institutions, mostly in the United States, but also in Canada, Mexico, Saudi Arabia and other countries.
Moves and Changes
The IASLC wants to stay updated on changes and moves our members make in their professional lives. To that end, we encourage you to reach out to us when you have news you wish to share, or when you hear of a change you feel we should know about. Please send any information to Director of Communications Jeff Wolf or Project Specialist Becky Bunn.
Invitation to Host APLCC 2018
The IASLC APLCC (Asian Pacific Lung Cancer Conference) meeting is soliciting bids for the APLCC IASLC conference in 2018. Attendance is expected to range from 800 to 1,000.
The conference must be located in the Asian-Pacific region and it will last three to four days.
Applications will be accepted after Dec. 1, 2015, and not later than Feb. 1, 2016. The applications will be reviewed by the IASLC Executive Committee/Board of Directors at the Board meeting in February 2016. Finalists will be notified in March 2016.
Please apply by email to Pia.Hirsch@iaslc.org no later than Feb. 1, 2016.
December 2015: The International Association for the Study of Lung Cancer (IASLC) and the Journal of Thoracic Oncology (JTO) are pleased to present this feature each month to highlight certain articles of interest. The selected articles each month will be made available to the public for a limited time at the time of print. The articles below from the December issue of JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
The IASLC Lung Cancer Staging Committee has embarked on revisions for the 8th edition of the TNM classification for lung cancer. The first two manuscripts describing the T and M descriptors were published in July and November. In this issue, Asamura and colleagues provide information on proposals for the revision of the N descriptors.
The NTRK1 NTRK2, and NTRK3 genes code for the tropomyosin-related kinase (Trk) proteins TrkA, TrkB, and TrkC. These proteins function during neuronal development. NTRK fusions have been described in NSCLC. This issue has a FAST TRACK article, a brief report from Farago et al describing promising activity of the Trk inhibitor entrectinib in NSCLC.
Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non–Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
The final featured article by Paz-Ares and coworkers is a report on the phase III MISSION placebo-controlled trial of sorafenib in relapsed/refractory NSCLC. There is an excellent accompanying editorial by Dr Keunchil Park: The MISSION: Impossible? No, the Journey Should Continue with Better Targeting! The IASLC also published a news release about this article.
Welcome New Members - Invite Colleagues!
COMPLIMENTARY Fellows/Residents/Students/Trainees Membership – Group Program Registration
Welcome New IASLC Members for November (listed by country, then name):
Lung Cancer Awareness Month 2015: Recap
Additionally, we created fact sheets that highlight information about lung cancer across the globe. We translated these fact sheets in to several different languages, including Chinese, Japanese, Spanish and Portugese. While Lung Cancer Awareness Month may be over, we encourage you to continue to use these fact sheets as a resource going forward. We plan to keep them updated and continue to use them as a source of information. You can look at and download all of the fact sheets on our Lung Cancer Awareness Page.
The IASLC also publicized several events taking place in Europe as part of Lung Cancer Awareness Month and a Denver television station interviewed Dr. Hirsch about immunotherapy. (Click here to watch the story.)
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
September 23 - 26 2018Toronto, Canada
November 8 - 10 2018Guangzhou, China
February 20 - 23 2019Santa Monica, California